We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.61%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$870M
AUM Growth
-$103M
Cap. Flow
-$99.3M
Cap. Flow %
-11.41%
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$31.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$18.9M
3
DXCM icon
DexCom
DXCM
+$12.6M
4
COO icon
Cooper Companies
COO
+$10.8M
5
ELV icon
Elevance Health
ELV
+$10.4M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$24.2M
2
MRK icon
Merck
MRK
+$22.8M
3
CI icon
Cigna
CI
+$15.1M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$14.7M
5
BSX icon
Boston Scientific
BSX
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSCR icon
26
Oscar Health
OSCR
$8.54B
$13.4M 1.54%
1,022,743
-339,678
-25% -$5.04M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$29B
$13M 1.5%
48,197
+31,197
+184% +$8.02M
RPRX icon
28
Royalty Pharma
RPRX
$25.8B
$12.8M 1.47%
411,000
-184,000
-31% -$5.83M
AXSM icon
29
Axsome Therapeutics
AXSM
$11.4B
$12.8M 1.47%
109,600
-13,000
-11% -$1.48M
HUM icon
30
Humana
HUM
$46.3B
$12.4M 1.42%
46,830
-8,400
-15% -$2.27M
DXCM icon
31
DexCom
DXCM
$33.1B
$10.6M 1.22%
+155,000
New +$12.6M
NBIX icon
32
Neurocrine Biosciences
NBIX
$16.8B
$9.93M 1.14%
89,817
-10,500
-10% -$1.33M
ZBH icon
33
Zimmer Biomet
ZBH
$18.7B
$9.87M 1.14%
87,250
-36,750
-30% -$3.93M
CI icon
34
Cigna
CI
$73.6B
$9.28M 1.07%
28,200
-50,185
-64% -$15.1M
COR icon
35
Cencora
COR
$62B
$9M 1.03%
32,375
-21,375
-40% -$5.37M
DHR icon
36
Danaher
DHR
$147B
$8.6M 0.99%
41,952
-22,000
-34% -$4.8M
CNC icon
37
Centene
CNC
$32.9B
$7.65M 0.88%
126,000
-69,482
-36% -$4.2M
DVAX
38
DELISTED
Dynavax Technologies
DVAX
$7.33M 0.84%
565,000
-274,131
-33% -$3.63M
TGTX icon
39
TG Therapeutics
TGTX
$7.52B
$7M 0.8%
177,500
-85,000
-32% -$2.86M
ABT icon
40
Abbott
ABT
$188B
$6.9M 0.79%
52,000
-76,000
-59% -$9.67M
BIIB icon
41
Biogen
BIIB
$30.6B
$6.77M 0.78%
49,500
-74,200
-60% -$10.6M
ALGN icon
42
Align Technology
ALGN
$12.5B
$6.59M 0.76%
41,500
-400
-1% -$78.5K
TMO icon
43
Thermo Fisher Scientific
TMO
$222B
$6.29M 0.72%
12,640
-3,000
-19% -$1.62M
HCA icon
44
HCA Healthcare
HCA
$89.6B
$5.8M 0.67%
16,778
-17,601
-51% -$5.66M
SNDX icon
45
Syndax Pharmaceuticals
SNDX
$1.82B
$5.32M 0.61%
433,000
+201,000
+87% +$2.84M
AVR
46
Anteris Technologies
AVR
$872M
$4.7M 0.54%
+1,290,000
New +$8.29M
ASTH icon
47
Astrana Health
ASTH
$1.86B
$4.65M 0.53%
150,000
+70,000
+88% +$2.33M
VRNA
48
DELISTED
Verona Pharma
VRNA
$4.44M 0.51%
+70,000
New +$4.19M
BDX icon
49
Becton Dickinson
BDX
$48.9B
$4.35M 0.5%
19,000
-28,900
-60% -$6.71M
CYTK icon
50
Cytokinetics
CYTK
$10.5B
$4.19M 0.48%
104,250
-45,000
-30% -$2.07M
1
2
3 4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rhenman & Partners Asset Management held 104 positions worth $870M, down 11% from $973M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $99.3M in Q1 2025, closing 10 positions and reducing 55 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Bristol-Myers Squibb worth $19.8M.

  • Rhenman & Partners Asset Management's largest Q1 2025 buy was Bristol-Myers Squibb: 325,000 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Glaukos in Q1 2025, an estimated $31.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2025 reduction was Inspire Medical Systems, cutting an estimated $24.2M.
  • Rhenman & Partners Asset Management fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $14.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $870M portfolio in Q1 2025.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 10 in Q1 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 11% quarter-over-quarter to $870M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2025, filed 14 May 2025.